academic article

• A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis..  Gastroenterology.  160:115-127.e30. 2021
• SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  72:2132-2140. 2021